Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2026-12-12
Target enrollment:
Participant gender:
Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.